Program
Leuprolide
Also written as “Leuprorelin”, “Leuprolide acetate” and “Leuprolide Acetate”.
Its studies are mostly in Prostatic Neoplasms · Puberty, Precocious · Alzheimer Disease · Endometriosis · Breast Neoplasms, led by 18 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Takeda | 60 open or running | phase 4since Apr 23, 2015 | Oct 16, 2008 | none ahead |
| Abbott | 50 open or running | phase 3since Feb 20, 2008 | Mar 20, 2003 | none ahead |
| AbbVie | 30 open or running | phase 4since Jul 9, 2010 | Apr 24, 2008 | none ahead |
| Daewoong Pharmaceutical | 31 open or running | phase 4since Jul 3, 2012 | Jul 3, 2012 | none ahead |
| GP-Pharm | 30 open or running | phase 3since Aug 8, 2005 | Aug 8, 2005 | none ahead |
| Astellas Pharma | 20 open or running | phase 4since Jan 25, 2017 | Sep 19, 2006 | none ahead |
| Chong Kun Dang Pharmaceutical | 20 open or running | phase 1since May 23, 2016 | May 23, 2016 | none ahead |
| Johnson & Johnson | 20 open or running | phase 2since Jun 17, 2009 | Jun 17, 2009 | none ahead |
| Oakwood Laboratories | 20 open or running | phase 3since Jan 26, 2004 | Jan 26, 2004 | none ahead |
| Voyager Pharmaceutical | 20 open or running | phase 2since Jun 25, 2003 | Jun 25, 2003 | none ahead |
| bharat-serums-and-vaccines-limited | 10 open or running | phase 3since May 31, 2021 | May 31, 2021 | none ahead |
| dongkook-pharmaceutical-co-ltd | 10 open or running | phase 3since Jun 13, 2024 | Jun 13, 2024 | none ahead |
| enteris-biopharma-inc | 10 open or running | phase 2since Oct 15, 2021 | Oct 15, 2021 | none ahead |
| Lee's Pharmaceutical | 10 open or running | no phasesince Aug 30, 2018 | Aug 30, 2018 | none ahead |
| LG Chem | 11 open or running | phase 4since Jul 6, 2026 | Jul 6, 2026 | Aug 30, 2029phase 4 · NCT07710430 |
| peptron-inc | 10 open or running | phase 1since Mar 2, 2021 | Mar 2, 2021 | none ahead |
| tolmar-inc | 10 open or running | phase 3since May 5, 2015 | May 5, 2015 | none ahead |
| zodiac-produtos-farmaceuticos-s-a | 10 open or running | phase 4since Mar 11, 2022 | Mar 11, 2022 | none ahead |
Also a collaborator on its studies: parexel.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 24 studies since Mar 20, 2003.
- May 5, 2015tolmar-inc's first study: phase 3 study in Puberty, PrecociousNew to tolmar-inctolmar-inc · NCT02452931 · 64 enrolled · United States, Argentina, Canada and more
- May 23, 2016Chong Kun Dang Pharmaceutical's first study: phase 1 study in Postmenopausal DisorderNew to Chong Kun Dang PharmaceuticalChong Kun Dang Pharmaceutical · NCT03233932 · 13 enrolled · Korea, Republic of
- Jan 12, 2017Phase 1 study in Prostatic NeoplasmsDaewoong Pharmaceutical · NCT03029533 · 44 enrolled
- Jan 25, 2017Phase 4 study in Prostatic NeoplasmsAstellas Pharma · NCT03035032 · 107 enrolled · Hong Kong, Indonesia, Malaysia and more
- Aug 30, 2018Lee's Pharmaceutical's first study: no phase study in Prostatic NeoplasmsNew to Lee's PharmaceuticalLee's Pharmaceutical · NCT03662958 · 48 enrolled · China
- Oct 2, 2018Phase 3 study in Puberty, PrecociousAbbVie · NCT03695237 · 45 enrolled · United States, Puerto Rico
- Mar 2, 2021peptron-inc's first study: phase 1 study in Prostatic NeoplasmsNew to peptron-incpeptron-inc · NCT04783636 · 40 enrolled
- Apr 8, 2021Phase 1 study in Puberty, PrecociousChong Kun Dang Pharmaceutical · NCT04840745 · 32 enrolled · Korea, Republic of
- May 31, 2021bharat-serums-and-vaccines-limited's first study: phase 3 study in Advanced Prostate AdenocarcinomaNew to bharat-serums-and-vaccines-limitedbharat-serums-and-vaccines-limited · NCT04914195 · 155 enrolled · India
- Oct 15, 2021enteris-biopharma-inc's first study: phase 2 study in EndometriosisNew to enteris-biopharma-incenteris-biopharma-inc · NCT05096065 · 16 enrolled · United States
- Mar 11, 2022zodiac-produtos-farmaceuticos-s-a's first study: phase 4 study in Prostatic NeoplasmsNew to zodiac-produtos-farmaceuticos-s-azodiac-produtos-farmaceuticos-s-a · NCT05304169 · 48 enrolled · Brazil
- Aug 29, 2023Phase 3 study in Puberty, PrecociousDaewoong Pharmaceutical · NCT06025409 · 79 planned · Korea, Republic of
- Jun 13, 2024dongkook-pharmaceutical-co-ltd's first study: phase 3 study in Advanced Prostate CancerNew to dongkook-pharmaceutical-co-ltddongkook-pharmaceutical-co-ltd · NCT06490328 · 161 enrolled · South Korea
- Jul 6, 2026LG Chem's first study: phase 4 study in Puberty, PrecociousNew to LG ChemLG Chem · NCT07710430 · 43 planned · South Korea
Ahead
- Aug 30, 2029Primary completion: phase 4 study in Puberty, PrecociousLG Chem · NCT07710430
TargetBeta
“Gonadotropin-releasing hormone receptor agonist; Gonadotropin-releasing hormone receptor agonist”ChEMBL 37, by rule
Other programs on GNRHR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| triptorelinrule | Ipsen | phase 4 | 21 |
| Goserelinrule | AstraZeneca | phase 4 | 14 |
| linzagolixrule | Kissei Pharmaceutical | phase 3 | 14 |
| GnRH Antagonist SHR7280 | Jiangsu HengRui Medicine | phase 3 | 10 |
| Gonadotropin-Releasing Hormonerule | Ferring Pharmaceuticals | phase 3 | 5 |
| leuprolide mesylaterule | foresee-pharmaceuticals-co-ltd | phase 3 | 3 |
Studies
All 38 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07710430Puberty, Precocious · South Korea | 4 | Recruiting | LG Chem | Aug 30, 2029 | 43 |
| NCT06490328Advanced Prostate Cancer · South Korea | 3 | Completed | dongkook-pharmaceutical-co-ltd | Jan 21, 2026 | 161 |
| NCT06025409Puberty, Precocious · Korea, Republic of | 3 | Recruiting | Daewoong Pharmaceutical | Feb 28, 2025 | 79 |
| NCT05304169Prostatic Neoplasms · Brazil | 4 | Completed | zodiac-produtos-farmaceuticos-s-a | Jun 15, 2018 | 48 |
| NCT05096065Endometriosis · United States | 2 | UNKNOWN | enteris-biopharma-inc | May 2022 | 16 |
| NCT04914195Advanced Prostate Adenocarcinoma · India | 3 | Completed | bharat-serums-and-vaccines-limited | Sep 29, 2022 | 155 |
| NCT04840745Puberty, Precocious · Korea, Republic of | 1 | UNKNOWN | Chong Kun Dang Pharmaceutical | Oct 2021 | 32 |
| NCT04783636Prostatic Neoplasms | 1 | UNKNOWN | peptron-inc | Jul 20, 2021 | 40 |
| NCT03695237Puberty, Precocious · United States, Puerto Rico | 3 | Completed | AbbVie | May 6, 2021 | 45 |
| NCT03662958Prostatic Neoplasms · China | – | UNKNOWN | Lee's Pharmaceutical | Oct 2018 | 48 |
| NCT03035032Prostatic Neoplasms · Hong Kong, Indonesia, Malaysia and more | 4 | Completed | Astellas Pharma | Nov 19, 2019 | 107 |
| NCT03029533Prostatic Neoplasms | 1 | UNKNOWN | Daewoong Pharmaceutical | Nov 2017 | 44 |
| NCT03233932Postmenopausal Disorder · Korea, Republic of | 1 | Completed | Chong Kun Dang Pharmaceutical | Jul 2017 | 13 |
| NCT02452931Puberty, Precocious · United States, Argentina, Canada and more | 3 | Completed | tolmar-inc | Sep 5, 2018 | 64 |
| NCT02427958Puberty, Precocious · China | 4 | Completed | Takeda | Nov 23, 2018 | 307 |
| NCT02085252Prostatic Neoplasms · France | 3 | Completed | Takeda | Nov 8, 2016 | 116 |
| NCT01634321Puberty, Precocious · Korea, Republic of | 4 | Completed | Daewoong Pharmaceutical | Aug 2012 | 63 |
| NCT01546649Premenopausal Breast Cancer · Japan | 3 | Completed | Takeda | Dec 2014 | 167 |
| NCT01546623Prostatic Neoplasms · Japan | 3 | Completed | Takeda | Apr 2014 | 160 |
| NCT01415960Prostatic Neoplasms · United States | 3 | Completed | GP-Pharm | May 2013 | 163 |
| NCT01161563Prostatic Neoplasms · United States | 4 | Completed | AbbVie | Apr 2011 | 118 |
| NCT01088529Prostatic Neoplasms · United States | 2 | Completed | Johnson & Johnson | Mar 2013 | 66 |
| NCT00924469Prostatic Neoplasms · United States | 2 | Completed | Johnson & Johnson | Feb 2012 | 58 |
| NCT00817739Prostatic Neoplasms | 2 | Completed | Takeda | Sep 2005 | 341 |
| NCT00776074Leiomyoma | 2 | Completed | Takeda | Jul 2007 | 80 |
| NCT00667446Puberty, Precocious · United States, Puerto Rico | 3 | Completed | AbbVie | Oct 2012 | 72 |
| NCT00660010Puberty, Precocious · United States | 3 | Completed | Abbott | Apr 2009 | 55 |
| NCT00635817Puberty, Precocious · United States, Puerto Rico | 3 | Completed | Abbott | Jan 2010 | 84 |
| NCT00630799Prostatic Neoplasms · United States | 3 | Terminated | GP-Pharm | Apr 2009 | 20 |
| NCT00626431Prostatic Neoplasms · United States | 3 | Completed | Abbott | Aug 2009 | 310 |
| NCT00598312Prostatic Neoplasms · United States | 3 | Completed | Oakwood Laboratories | Aug 2008 | 201 |
| NCT00378690Prostatic Neoplasms · Belgium, Czech Republic, Finland and more | 3 | Completed | Astellas Pharma | Jun 2011 | 706 |
| NCT00275262Hodgkin Disease · United States | 2 | Terminated | Abbott | Feb 2009 | 25 |
| NCT00128531Prostatic Neoplasms · United States, Austria, Czech Republic and more | 3 | Completed | GP-Pharm | 120 | |
| NCT00076531Prostatic Neoplasms | 3 | Completed | Oakwood Laboratories | Nov 2004 | |
| NCT00076440Alzheimer Disease · United States | 2 | Completed | Voyager Pharmaceutical | Mar 2007 | 90 |
| NCT00063310Alzheimer Disease · United States | 2 | Completed | Voyager Pharmaceutical | Feb 2006 | 90 |
| NCT00056654Prostatic Neoplasms · United States | – | Completed | Abbott | Jul 2004 | 164 |
How it is read
Names in the registry
- “Leuprorelin”, 4 entries
- “Leuprolide acetate”, 4 entries
- “Leuprolide”, 2 entries
- “Leuprolide Acetate”, 2 entries
- “TAP-144-SR(6M)”, 2 entries
Conditions, from the studies’ own filings
- Prostatic Neoplasms, 21 studies
- Puberty, Precocious, 10 studies
- Alzheimer Disease, 2 studies
- Endometriosis, 1 study
- Breast Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.